These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36551589)

  • 1. Systematic Investigation of the Multifaceted Role of
    Sun Q; Du J; Dong J; Pan S; Jin H; Han X; Zhang J
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implication and Oncogenic Role of PNPO in Pan-Cancer.
    Zhang L; Li X; Zhang J; Xu G
    Front Cell Dev Biol; 2021; 9():763674. PubMed ID: 35127701
    [No Abstract]   [Full Text] [Related]  

  • 3. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
    Wang Y; Gong H; Cao Y
    Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance and Prognostic Value of Human Soluble Resistance-Related Calcium-Binding Protein: A Pan-Cancer Analysis.
    Zhang J; Chen J; Shan B; Lin L; Dong J; Sun Q; Zhou Q; Han X
    Front Med (Lausanne); 2021; 8():752619. PubMed ID: 34869449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
    Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
    Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
    [No Abstract]   [Full Text] [Related]  

  • 6. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
    Ning Y; Li Y; Wang H
    Front Genet; 2023; 14():1108167. PubMed ID: 36713082
    [No Abstract]   [Full Text] [Related]  

  • 8. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
    Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of
    Li L; Li F; Xu Z; Li L; Hu H; Li Y; Yu S; Wang M; Gao L
    Front Pharmacol; 2023; 14():1213891. PubMed ID: 37680718
    [No Abstract]   [Full Text] [Related]  

  • 10. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
    Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
    Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3.
    Wu Y; Zhang B; Nong J; Rodrìguez RA; Guo W; Liu Y; Zhao S; Wei R
    Front Genet; 2023; 14():1045061. PubMed ID: 37035741
    [No Abstract]   [Full Text] [Related]  

  • 16. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 17. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
    Wen J; Mao X; Cheng Q; Liu Z; Liu F
    Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Prognostic and Immune Analysis of SLC41A3 in Pan-Cancer.
    Liu J; Zhang S; Dai W; Xie C; Li JC
    Front Oncol; 2020; 10():586414. PubMed ID: 33520701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.